This page provides a comprehensive overview of organizations involved in Alzheimer's disease research, drug development, and patient advocacy. It tracks the full ecosystem including pharmaceutical companies, biotechnology firms, nonprofits, patient advocacy groups, contract research organizations, and international programs.
| Company | AD Programs | Key Assets | Status |
|---|---|---|---|
| Eli Lilly | 4 | Donanemab, Remternetug, Solanezumab | Phase 3 |
| Biogen | 3 | Aduhelm, Leqembi (with Eisai) | Approved + Phase 3 |
| Roche | 5 | Gantenerumab, Crenezumab | Phase 3 |
| Eisai | 2 | Leqembi | Approved |
| AbbVie | 2 | ABBV-916 | Phase 1 |
| Novartis | 2 | Bilingual, CT1812 | Phase 1/2 |
| Merck | 1 | MK-2514 (GLP-1) | Phase 1 |
| Pfizer | 1 | PF-06423879 | Phase 1 |
| Company | Focus | Key Assets |
|---|---|---|
| UCB Pharma | Tau, Synuclein | Bepranemab |
| AstraZeneca | Neuroinflammation | AZD-5906 |
| Takeda | Amyloid | Multiple programs |
| Janssen | Tau, Neuroprotection | JNJ-63733657 |
| Sanofi | Tau | SAR-422459 |
| Company | Mechanism | Development Stage |
|---|---|---|
| AC Immune | Tau vaccine, α-syn vaccine | Phase 2/3 |
| Prothena | Prasinezumab (α-syn) | Phase 2 |
| Denali Therapeutics | LRRK2 inhibitor, ATN | Phase 2 |
| Athira Pharma | HGF/MET activator | Phase 2/3 |
| Cassava Sciences | Filamin A modulator | Phase 3 |
| Alzheon | Tau aggregation inhibitor | Phase 3 |
| ProMIS Neurosciences | Aβ oligomer antibody | Phase 2 |
| Acumen Pharmaceuticals | Aβ oligomer antibody | Phase 2 |
| Company | Novel Approach | Technology |
|---|---|---|
| Nodthera | NLRP3 inhibitor | Small molecule |
| Axsome Therapeutics | Sigma-1 agonist | AXS-05, AXS-060 |
| INmune Bio | TNF inhibitor | XPro1595 |
| Alector | TREM2 activator | Latozinemab |
| Lexeo Therapeutics | APOE4 gene therapy | LX1001 |
| Life Biosciences | Tau aggregation inhibitor | Multiple |
| Company | Approach | Target |
|---|---|---|
| Voyager Therapeutics | AAV gene therapy | Tau, Aβ |
| Prevail Therapeutics | AAV-GBA1 | Parkinson's |
| BlueRock Therapeutics | Cell therapy | Dopamine neurons |
| Sangamo Therapeutics | Zinc finger | Multiple |
| uniQure | AAV gene therapy | Huntingtin |
| Organization | Focus | Activities |
|---|---|---|
| Alzheimer's Drug Discovery Foundation (ADDF) | Drug discovery | Funding early-stage AD research |
| Bill & Melinda Gates Foundation | Global health | Neurodegeneration research |
| Chan Zuckerberg Initiative | Neurodegeneration challenge | Funding novel approaches |
| BrightFocus Foundation | AD, glaucoma, macular degeneration | Research grants |
| Organization | Region | Focus |
|---|---|---|
| Alzheimer's Association | US | Patient support, research funding |
| Alzheimer's Society | UK | Patient support, research |
| Alzheimer's Foundation of America | US | Patient care and support |
| Organization | Services | AD Expertise |
|---|---|---|
| IQVIA | Full-service | Strong |
| Catalent | Manufacturing | Strong |
| Charles River Laboratories | Preclinical | Strong |
| Covance | Full-service | Strong |
| Parexel | Clinical trials | Strong |
| Medpace | Clinical trials | Moderate |
| ICON PLC | Clinical development | Strong |
| Country/Region | Program | Focus |
|---|---|---|
| EU | Innovative Health Initiative | Public-private partnerships |
| UK | Dementia Research Institute | Basic research |
| Germany | DZNE (German Center for Neurodegenerative Diseases) | Translational research |
| Institution | AD Research Focus |
|---|---|
| Mayo Clinic | Tau pathology, biomarkers |
| UCLA Brain Research Institute | Amyloid, tau, clinical trials |
| Massachusetts General Hospital | Clinical trials, imaging |
| Banner Alzheimer's Institute | Prevention trials |
| UC San Diego | Stem cell research |
| Agency | Role |
|---|---|
| NIH/NIA | Research funding, clinical trials |
| FDA | Drug approval |
| CDC | Public health |
| Target | Companies | Status |
|---|---|---|
| Amyloid-beta | Eli Lilly, Biogen, Roche, Eisai | Approved/Phase 3 |
| Tau | Roche, Novartis, Athira, Alzheon | Phase 2/3 |
| α-Synuclein | Prothena, Roche | Phase 2 |
| Neuroinflammation | Nodthera, INmune Bio | Phase 2 |
| TREM2 | Alector | Phase 2 |
| Synaptic plasticity | Multiple | Early stage |